@Article{duepublico_mods_00071866,
  author = 	{Brandes, Jan Lewis
		and Diener, Hans-Christoph
		and Dolezil, David
		and Freeman, Marshall C.
		and McAllister, Peter J.
		and Winner, Paul
		and Klatt, Jan
		and Cheng, Sunfa
		and Zhang, Feng
		and Wen, Shihua
		and Ritter, Shannon
		and Lenz, Robert A.
		and Mikol, Daniel D.},
  title = 	{spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50{\%}, ≥75{\%}, and 100{\%} response},
  year = 	{2019},
  month = 	{Dec},
  day = 	{09},
  keywords = 	{Erenumab; chronic migraine; monthly migraine days; responder rates},
  abstract = 	{Objective: To assess the efficacy of erenumab across the spectrum of response thresholds (≥50{\%}, ≥75{\%}, 100{\%}) based on monthly migraine days (MMD) reduction in patients with chronic migraine from a 12-week, randomized study (NCT02066415). Methods: Patients (n{\thinspace}={\thinspace}667) received (3:2:2) placebo or erenumab 70/140{\thinspace}mg once-monthly. The proportion of patients achieving a given response threshold was assessed. A post-hoc analysis was conducted to contextualize the actual treatment benefit in subgroups of patients achieving (or not) specified response thresholds. Outcome measures included MMD, acute migraine-specific medication treatment days (MSMD) and disability. Results: The proportion of patients responding to erenumab exceeded that of placebo at the ≥50{\%} and ≥75{\%} response thresholds. At month 3, 39.9{\%} and 41.2{\%} of patients on erenumab 70 and 140{\thinspace}mg, respectively, achieved ≥50{\%} response versus placebo (23.5{\%}). Similarly, at month 3, 17.0{\%} and 20.9{\%} of patients on erenumab 70 and 140{\thinspace}mg, respectively, achieved ≥75{\%} response versus placebo (7.8{\%}). Compared with the overall erenumab-treated population (change in MMD: −6.6 [both 70 and 140{\thinspace}mg]), ≥50{\%} responders showed MMD reductions of −12.2/−12.5 for 70{\thinspace}mg/140{\thinspace}mg versus −2.6/−2.2 for those not achieving ≥50{\%} response. ≥75{\%} responders showed MMD reductions of −13.9/−14.8 for 70{\thinspace}mg/140{\thinspace}mg versus −5.0/−4.3 for those not achieving ≥75{\%} response. Relative improvements in MSMD and disability were observed in responders versus overall erenumab-treated population. Conclusion: For erenumab-treated patients achieving ≥50{\%} response, the actual reduction in MMD was almost twice that of the overall population. These findings provide context for setting realistic expectations regarding actual treatment benefit experienced by patients responding to treatment.},
  note = 	{deepgreen SAGE},
  note = 	{Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-gef{\"o}rderten) Allianz- bzw. Nationallizenz frei zug{\"a}nglich.
<hr />This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.},
  note = 	{<p>Brandes, J. L., Diener, H.-C., Dolezil, D., Freeman, M. C., McAllister, P. J., Winner, P., Klatt, J., Cheng, S., Zhang, F., Wen, S., Ritter, S., Lenz, R. A., {\&}amp; Mikol, D. D. (2020). The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50{\%}, ≥75{\%}, and 100{\%} response. <em>Cephalalgia</em>, 40(1), 28--38. <a href="https://doi.org/10.1177{\%}2F0333102419894559">https://doi.org/10.1177/0333102419894559</a></p>

<p>Article first published online: December 9, 2019</p>

<p>{\&}{\#}xa0;</p>},
  doi = 	{10.1177/0333102419894559},
  url = 	{https://duepublico2.uni-due.de/receive/duepublico_mods_00071866},
  url = 	{https://doi.org/10.1177/0333102419894559},
  file = 	{:https://duepublico2.uni-due.de/servlets/MCRFileNodeServlet/duepublico_derivate_00071696/Brandes_et_al_Spectrum_response_erenumab.pdf:PDF},
  language = 	{en}
}